enGene Therapeutics Inc. (NASDAQ:ENGN)
| Market Cap | $116.61M-76.5% |
| Revenue (ttm) | $0 |
| Net Income | -$4.90M+94.8% |
| EPS | -$0.28+85.3% |
| Shares Out | 67.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Feb 2, 2015 |
| Volume | 556,716 |
| Open | $1.74 |
| Previous Close | $1.76 |
| Day's Range | $1.69 - $1.79 |
| 52-Week Range | $1.40 - $12.25 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $4.33(+148.85%) |
| Earnings Date | Dec 22, 2026 |
About ENGN
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
enGene Therapeutics Inc. Stock Analysis — InsiderScore
enGene Therapeutics Inc. scored higher than 3% of companies evaluated by InsiderBuying, and ranked 90th out of 101 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at enGene Therapeutics Inc. bought $10.1K of stock across 1 purchase in the last 90 days, the largest of them $10.1K.
None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating ENGN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Dec 22, 2026Earnings report
$ENGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ENGN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ENGN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ENGN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ENGN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ENGN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ENGN
| AVSCAvantis U.S. Small Cap Equity ETF | $8.85K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ENGN’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upgrade to Outperform, positive pivotal trial data updates, and planned BLA submission generate bullish sentiment.
Recent Insider Activity
Insider Score Trend Over Time
-19.7 since Sep 25Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
